Michael Gerber
Family · Mason City, IANPI 1639607757
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 354 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 354 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$923
- Johnson & Johnson$812
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$800
- Teva Pharmaceuticals USA, Inc.$723
- Lundbeck LLC$446
- Otsuka America Pharmaceutical, Inc.$374
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,47999%
- Education$731%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 79 | $923 |
| Johnson & Johnson | 52 | $812 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $800 |
| Teva Pharmaceuticals USA, Inc. | 39 | $723 |
| Lundbeck LLC | 28 | $446 |
| Otsuka America Pharmaceutical, Inc. | 23 | $374 |
| Sunovion Pharmaceuticals Inc. | 16 | $268 |
| Axsome Therapeutics, Inc. | 13 | $238 |
| Vanda Pharmaceuticals Inc. | 10 | $210 |
| Alkermes, Inc. | 12 | $193 |
| Neurocrine Biosciences, Inc. | 11 | $181 |
| Indivior Inc. | 9 | $157 |
| Ironshore Pharmaceuticals Inc. | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 3 | $50 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Harmony Biosciences LLC | 1 | $18 |
| Corium, LLC | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $16 |
| Tris Pharma Inc | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$5,552 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 125 | $150,337 |
| IngrezzaValbenazine Tosylate | 13 | $114,667 |
| RexultiBrexpiprazole | 60 | $76,197 |
| Lurasidone Hcl | 180 | $53,081 |
| Abilify MaintenaAripiprazole | 15 | $44,194 |
| CaplytaLumateperone Tosylate | 36 | $41,843 |
| Aripiprazole | 329 | $32,506 |
| AustedoDeutetrabenazine | 11 | $26,988 |
| Risperdal ConstaRisperidone Microspheres | 29 | $18,863 |
| Clozapine | 181 | $17,249 |
| TrintellixVortioxetine Hydrobromide | 24 | $14,506 |
| Quetiapine Fumarate | 435 | $9,560 |
| Paliperidone ErPaliperidone | 42 | $9,078 |
| Buspirone Hcl | 493 | $7,115 |
| Duloxetine Hcl | 234 | $6,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $923 | $150,337125 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $374 | $120,39275 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $181 | $114,66713 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $800 | $41,84336 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $723 | $26,98811 claims |
| Johnson & JohnsonRisperdal Consta | $812 | $18,86329 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Mason City
- Kaci YoungerMason City$4K
- Krishna HughesMason City$4K
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.